Why the study?
Conventional therapies for epicardial vasospasm-induced ventricular arrhythmias lack randomized trial evidence, and management after treatment failure remains unclear despite abnormal sympathetic activity playing a role.
Does the addition of nebivolol improve clinical stability and prevent recurrent arrhythmias in patients with high-risk epicardial vasospasm and concomitant ventricular tachycardia refractory to conventional therapy?
Does the addition of nebivolol improve clinical stability and prevent recurrent arrhythmias in patients with high-risk epicardial vasospasm and concomitant ventricular tachycardia refractory to conventional therapy?
Nebivolol, a highly selective beta-1 blocker, safely improved symptoms and prevented recurrent ventricular arrhythmias in three patients with epicardial vasospasm refractory to conventional vasodilator therapy, challenging the dogma that all beta-blockers are strictly contraindicated in this setting.
Nebivolol stabilized refractory vasospasm-induced VT in three cases; leaves open whether selective beta-blockade merits prospective evaluation.
Background: Patients who experience ventricular tachycardia and cardiac arrest induced by epicardial vasospasm are at high risk for recurrent cardiac events. Conventional treatment includes calcium channel-blockade, long-acting nitrates, and the withdrawal of beta-blockade. These guidelines have not been proven effective in randomized controlled trials, and the evidence against beta-blockade is primarily anecdotal. Ongoing medical management in the setting of treatment failure is unclear, but abnormal sympathetic activity has been implicated in both spasm and ventricular arrhythmias. Case presentation: We describe three patients with spasm-related ventricular arrhythmias and unacceptably poor response to conventional treatment. Clinical stability and asymptomatic status were achieved following the addition of nebivolol, a third-generation, lipophilic beta-1-specific beta-blocker. Discussion: Selective beta-blockade may represent a therapeutic option in patients with high-risk epicardial spasm and ventricular arrhythmias. Furthermore, the apparent success of nebivolol in this setting suggests that hyperactive sympathetic input may represent a causal or aggravating factor in spasm-associated ventricular arrhythmias.
No takes yet. Share an insight, caveat, or question.
Miner et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: